Table 3. Annotation format for linking MAxO terms to diseases.

Annotations are shown for congenital myasthenic syndrome 4A (MONDO:0011600) and congenital myasthenic syndrome 4B (MONDO:0014586). Both have the same disease annotations, but medical action serotonin-norepinephrine reuptake inhibitor agent therapy (MAXO:0000214) have different relations where it is a recommended treatment (treats) 4A, but it is contraindicated (contraindicated) in 4B. The evidence code PCS corresponds to ECO:0006016 (author statement from published clinical study).

Field	Example 1 (treatment)	Example 2 (treatment contraindicated)
Disease ID	MONDO:0011600	MONDO:0014586
Disease Name	congenital myasthenic syndrome 4A	congenital myasthenic syndrome 4B
MAxO ID	MAXO:0000214	MAXO:0000214
MAxO label	serotonin-norepinephrine reuptake inhibitor agent therapy	serotonin-norepinephrine reuptake inhibitor agent therapy
Relation	treats	contraindicated
HPO id	HP:0003473	HP:0003473
HPO label	Fatigable muscle weakness	Fatigable muscle weakness
Evidence code	PCS	PCS
Extension id	CHEBI:5118	CHEBI:5118
Extension label	fluoxetine	fluoxetine
Source	PMID:29395675	PMID:29367459
Curated by	orcid:0000-0002-9353-5498	orcid:0000-0002-6889-0121
Comment	Fluoxetine is a serotonin-norepinephrine reuptake inhibitor that also has been found to decrease channel-opening duration and in this study is used off-label for patients with slow-channel CMS.	Fluoxetine use in patients with fast-channel CMS, in whom channel-opening duration is already too short, causes worsening of symptoms.